# Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

* Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies.
* The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer.
* A review of 221 clinical trials informed the development of the predictive algorithm.
* Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes.
* Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use.

 Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). The technology is integrated into the company’s RADR(R) platform, which supports AI-guided drug development.

 The launch comes at a time when the global market for combination cancer therapies is projected to surpass $50 billion by 2030, according to Lantern’s…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

 About AINewsWire

 AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

 AINW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit www.AINewsWire.com

 Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer

 AINewsWireLos Angeles, CAwww.AINewsWire.com310.299.1717 OfficeEditor@AINewsWire.com

 AINewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ainw/lantern-pharma-inc-nasdaq-ltrn-launches-ai-tool-to-predict-efficacy-of-cancer-drug-combinations/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/lantern-pharma-unveils-ai-tool-to-predict-cancer-drug-efficacy/d698f2309cf3d2e4f973ee0c4258e91b) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1mjeqtq/lantern_pharma_unveils_ai_tool_to_predict_cancer/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/6/ideaAt4T.webp)